Peptides – shipping from Europe

Research Disclaimer: This article is intended for educational and informational purposes regarding the chemical and biochemical properties of research compounds. All information is provided strictly in a scientific context. This content does not constitute medical advice, nor does it promote the use of any compound for human or veterinary application. All compounds referenced are for laboratory research use only.

Cagrilintide is a long-acting synthetic analogue of amylin (also known as islet amyloid polypeptide, or IAPP), a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells. Amylin plays a complementary role to insulin in regulating postprandial blood glucose, primarily through effects on gastric emptying, glucagon suppression, and central satiety signalling. Cagrilintide was developed to recapitulate these biological activities with extended duration of action, and has been investigated in research settings both as a standalone compound and in combination with GLP-1 receptor agonist peptides.

Amylin Biology: Research Background

Amylin was first characterised in the late 1980s by researchers studying the major protein component of the pancreatic amyloid deposits found in the islets of Langerhans in individuals with type 2 diabetes. Subsequent work established amylin not merely as a pathological deposit component, but as an endogenous peptide hormone with distinct physiological roles secreted in concert with insulin.

Key amylin-mediated effects characterised in research include: slowing of gastric emptying rate, suppression of postprandial glucagon secretion, and reduction of food intake through central amylin receptor activation in the area postrema and nucleus accumbens. These actions complement insulin’s effects on postprandial glucose management, making amylin biology an important area of metabolic research.

Native amylin has significant limitations as a research compound, most notably its strong tendency to aggregate and form amyloid fibrils under physiological conditions — a property that complicates its use in experimental systems. Cagrilintide was developed with specific structural modifications to prevent aggregation while retaining amylin receptor activity.

Molecular Structure and Chemical Profile

Amylin Receptor System

Amylin exerts its biological effects through a family of receptors formed by the combination of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). Three amylin receptor subtypes have been characterised — AMY1, AMY2, and AMY3 — corresponding to combinations of CTR with RAMP1, RAMP2, and RAMP3 respectively.

These receptors are expressed in multiple tissues relevant to metabolic regulation, including the central nervous system (particularly the area postrema and nucleus accumbens), the stomach, and the kidney. Cagrilintide’s high-affinity binding to this receptor family forms the basis for its use as a research tool in amylin receptor biology studies.

Combination Research with GLP-1 Agonists

A scientifically significant aspect of cagrilintide research is its investigation in combination with GLP-1 receptor agonist peptides, including semaglutide. The rationale for this combination is mechanistically grounded: GLP-1 receptors and amylin receptors are expressed in overlapping but distinct brain regions and peripheral tissues, and their activation is associated with complementary rather than redundant mechanisms of action.

GLP-1 receptor activation primarily influences insulin secretion and hepatic glucose production, while amylin receptor activation preferentially affects gastric emptying rate and central satiety circuits. Research has explored whether simultaneous activation of both receptor systems produces additive or synergistic effects on metabolic parameters in experimental models.

Preclinical research using rodent models has examined combined GLP-1R/amylin receptor activation, with studies reporting effects on body weight, food intake, and glucose homeostasis parameters. These findings have driven interest in this combination as a research model for dual-agonist approaches to metabolic biology.

Gastric Emptying Research

A key mechanistic focus of amylin and cagrilintide research is their effects on gastric emptying rate. Amylin has been established as a physiological regulator of gastric motility, with receptor-mediated mechanisms slowing the transit of nutrients from the stomach to the small intestine — thereby modulating the rate of postprandial glucose absorption.

In vitro and ex vivo studies have characterised the mechanisms by which amylin receptor activation influences gastric smooth muscle activity and vagal nerve signalling. Cagrilintide has been used as a research tool in these experimental systems to study amylin receptor-mediated gastric effects with the methodological advantages of a non-aggregating, long-acting analogue.

Laboratory Handling

Note: Cagrilintide is available from Aminopept for laboratory research use only. This compound is not approved for human therapeutic use. All information is for scientific reference.

——————————————————————————————————-

Cagrilinitide is available in research-grade, lyophilized form from the Aminopept research catalogue. Supplied for laboratory and in-vitro research use only.

→ View Cagrilinitide in the research catalogue